





A unit of Artemis Medicare Services Ltd.

May 12, 2025

The Secretary,
National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E),
Mumbai – 400 051

The Secretary,
BSE Limited
Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai – 400 001

NSE Code: ARTEMISMED Scrip Code: 542919

Sub: Earnings Presentation – Q4 and FY2025

Dear Sir/Ma'am,

With reference to the captioned subject, please find attached herewith the earnings presentation for the quarter/ year ended March 31, 2025.

The presentation is also available on the website of the Company at www.artemishospitals.com/investors.

Submitted for your information & records.

Thanking you.

Yours faithfully,
For Artemis Medicare Services Limited

Company Secretary & Compliance Officer

Encl: As above

Poonam Makkar











Care for Customer

Respect for Associates

Excellence through Teamwork

Always Learning

Trust Mutually

Ethical Practices



(BSE: 542919; NSE: ARTEMISMED)

Earnings Presentation Q4 and FY2025

Artemis Hospitals : At a Glance



Established in July 2007 by promoters of Apollo Tyres (67% ownership), Artemis Hospital is one of the leading healthcare service providers in Delhi NCR

800+ beds across Artemis Hospital Group

300+ beds upcoming in Raipur facility

Attractive platform for leading doctors given the strength of the brand

Business tie-up with over 100 corporates, both private and PSUs

Expanding footprint in Tier 1 & 2 cities through a chain of asset light centres

High quality of service supported by state-of-the-art Equipment and Technology

One of the most preferred destination for international patients

Diverse business across multi-speciality, cardiac and maternity segments

Artemis Cardiac Care, a joint venture with Philips, operating cardiac care centres across India



500+ Full time Doctors


40+ Specialities


12 Centres of Excellence


Consolidated Financial Highlights – Q4 FY25



Key Financials (INR Mn)









Onkar Kanwar Chairman

"Artemis concluded FY25 on a strong and positive trajectory, delivering consistent performance and steady growth across the year. We have continued to advance in both clinical excellence and operational capabilities, reaffirming our commitment to provide high-quality, accessible healthcare to the communities we serve. During the year we also inaugurated our third tower, which will be commissioned in a phase-wise manner to accommodate the increasing demand from our growing patient base.

To fuel our next growth phase, we raised Rs 330 Crores from the International Finance Corporation (IFC), enabling strategic expansion across Delhi NCR and select Tier 2 cities through both brownfield and greenfield projects. The Board has approved a long-term Operations & Management and Medical Services Agreement for a 300+ bed super-speciality hospital in Raipur. This deal marks a key step in expanding our footprint in Central India and reinforces our mission to deliver advanced healthcare solutions across geographies.

As we look ahead, our unwavering focus remains on creating long-term value for our patients, shareholders, and employees, while building Artemis into one of India's most trusted and respected healthcare brands."

FRITDA Includes Other Income

Margins calculated on Net Revenue from Operations


Accreditations and Centres of Excellence



Accreditations



Centres of Excellence



High End Quaternary Care Facilities

MAGNETOM Lumina

ECHO Machine





128 slice Cardiac CT



Warm Ambience



Pre and Post Op Care

Strategic Growth Vision





Artemis Hospital, Gurgaon



- We have opened the third tower, taking the capacity to 700+ beds, making it one of the largest hospitals in Delhi-NCR.
- The enhanced capacity will allow us to reap the benefits of economies of scale, further enhancing our operational efficiency. This tower shall be operationalised in a phase-wise manner.



Expansion in Super Speciality segment



- Announced 300+ bed super speciality hospital in Raipur
- Further capacity enhancement by adding super speciality hospitals in the group in Delhi NCR / select Tier – 2 cities



Asset Light Model



Focus on strengthening the operations of the asset light hospital in a value accretive manner



Overseas
Operations and
Management



- Operating our first hospital with ~80 beds branded as 'Artemis Curepipe Hospital', which started in FY24
- Further plans in place to increase Artemis footprint in other international locations




- In view of the growing demand for affordable healthcare, expanding our bed capacity in existing and new hospitals
- Enhancing operational efficiency to cater growing demand
- Brand recognition and geographical advantage backed by the best-in-class technology and team of accomplished medical practitioners to reap the benefits of this growth





Artemis Hospital, Gurgaon

Artemis Hospital Overview



Provides high end tertiary and quaternary care services across more than 40 specialities

First hospital in Gurgaon to get accredited by the Joint Commission International (JCI), in 2013

First Hospital in Haryana to get National Accreditation Board of Hospital (NABH) within 3 years of start up


First hospital in North India to have M6 Cyber Knife in 2017


12 Centres of Excellence at the hospital

| Period | ARPOB | Patient Volumes | Surgeries Performed | Avg. Operational Census Beds | Occupancy % | ALOS |
|---------|------------|-----------------|------------------------|------------------------------|-------------|------|
| Q4 FY25 | INR 82,800 | 93,443 | 3,340 | 522 | 60.8% | 3.6 |
| FY25 | INR 80,200 | 381,968 | 13,761 | 489 | 64.1% | 3.6 |











EBITDA and EBITDA Margin







Key Highlights

Reported 12.3% revenue
CAGR and 34.0% EBITDA
CAGR during FY23-25. The
strong growth in financial
metrics has been driven by:


- Leveraging economies of scale to improve operational efficiency through better allocation of fixed costs
- Plugging revenue leakages and running cost optimisation programs
- Supply chain and energy efficiency optimisations


Note

EBITDA Includes Other Income


^{2.} Margins calculated on Net Revenue from Operations















Artemis' Ventures



Overview



Management Team





Onkar Kanwar Chairman

- A visionary entrepreneur, plays a pivotal role in the company's operations and articulation of its business philosophy
- · Chairman of BRICS Business Council, India
- Served as the President of FICCI, Chairman of the automotive Tyre Manufacturers' Association in the past



Dr. Devlina Chakravarty *Managing Director*

- Started her career in 1993 as a radiologist trained from Mumbai University. She did fellowships programmes from University of Berlin (Germany), UCLA (Los Angeles) and Brigham & Women (Boston)
- Before joining Artemis in 2007, worked as senior faculty & program director in radiology in different reputed hospitals in Delhi



Sanjiv Kumar Kothari Chief Financial Officer

- Qualified Chartered Accountant with 30 years of expertise in Finance & Accounts domain
- Spearheading the Finance team at Artemis since 2013
- Part of Apollo International as VP Accounts for 2+ years; prior to Apollo, worked for Ultratech cement & Gujrat Perstrop Electronics Ltd



Ashutosh Kumar Jha
Chief – Strategy, M&A,
Investor Relations and
Organization Growth

- IIM and IIT alumnus with expertise in Strategy, M&A and Investments
- 18 years of experience across industries and private equity
- Previously Associated with Max Healthcare as Director and Head -Growth and M&A



Flt. Lt. Saras Malik Chief People Officer

- 23 years of managerial experience in Human Resources and Administration under the Indian Air Force and resultoriented measures of the Corporate
- Associated with Artemis for over 9
 years. Prior to joining Artemis Hospital,
 she has worked with Fortis Healthcare
 for more than 5 years



Dr. Manju Aggarwal Chief Medical Services & Chairperson -Nephrology

- Worked as a Senior Consultant in Nephrology at Indraprastha Apollo Hospital, Delhi for 17 years
- Joined Artemis Hospitals as the Head of Nephrology and Kidney Transplantation in February 2012



Dr. Vishal Arora Chief of Business Transformation and Operational Excellence

- Holds an MBA healthcare from IIHMR Jaipur, senior leadership program from IIMA
- Extensive experience in Hospital
 Operations, Cost Optimization, Revenue
 Enhancement, Business Process
 Reengineering and has worked with all leading hospital across the country

Board of Directors



Mr. Onkar Kanwar

Chairman and Non-Executive Director

- Former President of FICCI & ICC India, a former Director with the India's ECGC and KSIC, and former Chairman of ATMA
- Closely associated with leading national and international organizations

Dr. Devlina Chakravarty

Managing Director

- Completed her fellowships/ preceptorship programmes from University of Berlin, UCLA (LA) and Brigham & Women (Boston) in Head and Neck & Body Imaging
- Worked as senior faculty and Programme Director in Radiology in different reputed hospitals in Delhi before joining Artemis

Mr. Neeraj Kanwar

Non-Executive Director

- An Engineering graduate from Lehigh University and has been associated with the company since 2008
- Currently holding the position of Vice Chairman and Managing Director of Apollo Tyres and also served as the Chairman of the Automotive Tyre Manufacturer's Association

Ms. Shalini Kanwar Chand

Non-Executive Director

- Founder and Chairperson of Pristine International Holdings
- Graduated from the University of Delhi and Post Graduation from Swinburne University of Technology, Australia

Mr. Sunam Sarkar

Non-Executive Director

- Has extensive experience in sales, marketing, business operations, finance and corporate strategy.
- Graduated from Calcutta University, holds a Diploma in International Management from INSEAD, France, and a Master's degree in Management from Lancaster University, UK.

Mr. Vinod Rai

Independent Director

- Former Comptroller and Auditor General of India and former Chairman of the United Nations Panel of External Auditors
- A distinguished visiting research fellow at the Institute of South Asian Studies at the National University of Singapore

Ms. Pallavi Shroff

Independent Director

- Managing Partner & National Practice Head, Dispute Resolution of Shardul Amarchand Mangaldas & Co.
- Graduated from University of Delhi, Master of Management Studies from JBIMS and LLB from Government Law College, Mumbai

Mr. Akshay Chudasama Independent Director

- Managing Partner of Shardul Amarchand Mangaldas & Co.
- Expertise in cross-border M&A and Private Equity
- Graduated from University of Bombay and LLB from London School of Economics, UK

Ms. Deepa Gopalan Wadhwa

Independent Director

- Served as Ambassador of India to Japan (2012-2015), Qatar (2009-2012) and Sweden (2005-2009)
- A graduate from Madras University, she has an undergraduate degree in Chemistry and a post graduate degree in English Literature

Mr. Sanjib Sen

Independent Director

- Senior Advocate at Supreme Court of India and has expertise in Constitutional Law, Corporate and taxation laws, Criminal and Civil laws
- Presently he is member of panel of Arbitrators of Indian Council of Arbitration at FICCI

Mr. Sunil Tandon

Independent Director

 Mechanical Engineer from Delhi College of Engineering and MBA with a gold medal from FMS, University of Delhi

Q4 FY25 Operational Performance - Artemis Gurgaon





FY25 Operational Performance - Artemis Gurgaon








Financials


Historical Performance (Consolidated)




(INR Mn)

Gross Revenue





Quarterly Performance Trend



Note:

L. EBITDA Includes Other Income

[.] Margins calculated on Net Revenue from Operations

Q4 and FY25 Financial Performance (Consolidated)



| Particulars (INR Mn) | Q4 FY25 | Q4 FY24 | YoY% | Q3 FY25 | QoQ% | FY25 | FY24 | YoY% |
|--|---------|---------|-------|---------|-------|-------|-------|-------|
| Gross Revenue | 2,521 | 2,357 | 7.0% | 2,431 | 3.7% | 9,819 | 9,222 | 6.5% |
| Net Revenue from Operations | 2,399 | 2,252 | 6.5% | 2,324 | 3.2% | 9,369 | 8,786 | 6.6% |
| Other Income | 123 | 19 | | 88 | | 330 | 74 | |
| Total Income | 2,522 | 2,271 | 11.1% | 2,412 | 4.6% | 9,699 | 8,859 | 9.5% |
| Operative Expenses | 1,459 | 1,341 | 8.8% | 1,404 | 3.9% | 5,652 | 5,403 | 4.6% |
| Employee Benefit Expenses | 391 | 361 | 8.6% | 375 | 4.5% | 1,484 | 1,389 | 6.8% |
| Other expenses | 189 | 171 | 10.7% | 170 | 11.4% | 715 | 666 | 7.4% |
| EBITDA | 482 | 399 | 21.1% | 463 | 4.3% | 1,848 | 1,401 | 31.9% |
| EBITDA Margin | 20.1% | 17.7% | | 19.9% | | 19.7% | 15.9% | |
| Depreciation and amortisation expenses | 117 | 110 | 6.4% | 115 | 2.6% | 452 | 403 | 12.0% |
| EBIT | 365 | 288 | 26.7% | 348 | 4.8% | 1,396 | 997 | 40.0% |
| EBIT Margin | 15.2% | 12.8% | | 15.0% | | 14.9% | 11.4% | |
| Finance Cost | 78 | 86 | -8.7% | 80 | -2.1% | 319 | 313 | 2.1% |
| PBT | 287 | 202 | 41.6% | 268 | 6.9% | 1,077 | 685 | 57.3% |
| Total tax | 57 | 59 | -3.2% | 62 | -7.6% | 255 | 193 | 32.0% |
| PAT | 229 | 143 | 60.3% | 206 | 11.3% | 822 | 491 | 67.2% |
| PAT Margin | 9.6% | 6.4% | | 8.9% | | 8.8% | 5.6% | |

EBITDA Includes Other Income

^{2.} Margins calculated on Net Revenue from Operations

Q4 and FY25 Financial Performance (Standalone)



| Particulars (INR Mn) | Q4 FY25 | Q4 FY24 | YoY% | Q3 FY25 | QoQ% | FY25 | FY24 | YoY% |
|--|---------|---------|-------|--------------|-------|-------|-------|-------|
| Gross Revenue | 2,466 | 2,272 | 8.5% | 2,375 | 3.8% | 9,574 | 8,875 | 7.9% |
| Net Revenue from Operations | 2,348 | 2,169 | 8.3% | 2,269 | 3.5% | 9,133 | 8,452 | 8.0% |
| Other Income | 122 | 19 | | 88 | | 329 | 73 | |
| Total Income | 2,470 | 2,187 | 12.9% | 2,357 | 4.8% | 9,462 | 8,525 | 11.0% |
| Operative Expenses | 1,430 | 1,284 | 11.4% | 1,373 | 4.1% | 5,516 | 5,201 | 6.1% |
| Employee Benefit Expenses | 380 | 348 | 9.3% | 363 | 4.5% | 1,437 | 1,336 | 7.6% |
| Other expenses | 183 | 176 | 3.9% | 164 | 11.5% | 681 | 631 | 7.9% |
| EBITDA | 478 | 380 | 25.8% | 456 | 4.7% | 1,828 | 1,357 | 34.7% |
| EBITDA Margin | 20.3% | 17.5% | | 20.1% | | 20.0% | 16.1% | |
| Depreciation and amortisation expenses | 112 | 105 | 7.5% | 109 | 2.8% | 430 | 380 | 13.1% |
| EBIT | 365 | 275 | 32.7% | 347 | 5.3% | 1,397 | 976 | 43.1% |
| EBIT Margin | 15.6% | 12.7% | | <i>15.3%</i> | | 15.3% | 11.6% | |
| Finance Cost | 75 | 81 | -6.8% | 77 | -1.6% | 305 | 296 | 3.0% |
| PBT | 290 | 194 | 49.1% | 270 | 7.2% | 1,093 | 680 | 60.6% |
| Total tax | 58 | 55 | 4.9% | 63 | -7.5% | 258 | 189 | 36.5% |
| PAT | 232 | 139 | 66.6% | 208 | 11.7% | 835 | 491 | 69.8% |
| PAT Margin | 9.9% | 6.4% | | 9.2% | | 9.1% | 5.8% | |

EBITDA Includes Other Income

^{2.} Margins calculated on Net Revenue from Operations

Balance Sheet Overview



| Standa | alone | | Consolidated | | | | |
|--|----------------|--------------|---|----------------|--------------|--|--|
| Particulars (INR Mn) | FY25 | FY24 | Particulars (INR Mn) | FY25 | FY24 | | |
| Total Shareholders Funds | 8,418 | 4,516 | Total Shareholders Funds | 8,436 | 4,547 | | |
| Total Loans | 2,360 | 2,382 | Total Loans | 2,458 | 2,535 | | |
| Other Long Term Liabilities / Provisions | 897 | 1,057 | Other Long Term Liabilities / Provisions | 882 | 1,045 | | |
| Total Sources of Funds | 11,675 | 7,955 | Total Sources of Funds | 11,776 | 8,127 | | |
| Net Fixed Assets Other Non Current Assets | 7,695 463 | 7,327 513 | Net Fixed Assets Other Non Current Assets | 7,851 334 | 7,527 387 | | |
| Total Non Current Assets | 8,158 | 7,840 | Total Non Current Assets | 8,185 | 7,914 | | |
| Net Current Assets Cash and Bank Balances | (415) 3,932 | (465) 580 | Net Current Assets Cash and Bank Balances | (365) 3,956 | (400) 613 | | |
| Total Application of Funds | 11,675 | 7,955 | Total Application of Funds | 11,776 | 8,127 | | |

Disclosure



This presentation contains statements that contain "forward looking statements" including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Artemis Medicare Services future business developments and economic performance.

While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Artemis Medicare Services Limited undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information, please contact:

Sanjiv K Kothari Simran Malhotra / Anvita Raghuram

Chief Financial Officer Churchgate Partners
Artemis Medicare Services Ltd.

+91 124 4511 111 +91 22 6169 5988

Sanjiv.kothari@artemishospitals.com Artemisteam@churchgatepartners.com